Skip to main content
Nutrients logoLink to Nutrients
. 2020 Apr 24;12(4):1193. doi: 10.3390/nu12041193

A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis

Liang Chen 1, Chun Hu 2, Molly Hood 3, Xue Zhang 1, Lu Zhang 1, Juntao Kan 1, Jun Du 1,*
PMCID: PMC7230237  PMID: 32344708

Abstract

Novel coronaviruses (CoV) have emerged periodically around the world in recent years. The recurrent spreading of CoVs imposes an ongoing threat to global health and the economy. Since no specific therapy for these CoVs is available, any beneficial approach (including nutritional and dietary approach) is worth investigation. Based on recent advances in nutrients and phytonutrients research, a novel combination of vitamin C, curcumin and glycyrrhizic acid (VCG Plus) was developed that has potential against CoV infection. System biology tools were applied to explore the potential of VCG Plus in modulating targets and pathways relevant to immune and inflammation responses. Gene target acquisition, gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment were conducted consecutively along with network analysis. The results show that VCG Plus can act on 88 hub targets which are closely connected and associated with immune and inflammatory responses. Specifically, VCG Plus has the potential to regulate innate immune response by acting on NOD-like and Toll-like signaling pathways to promote interferons production, activate and balance T-cells, and regulate the inflammatory response by inhibiting PI3K/AKT, NF-κB and MAPK signaling pathways. All these biological processes and pathways have been well documented in CoV infections studies. Therefore, our findings suggest that VCG Plus may be helpful in regulating immune response to combat CoV infections and inhibit excessive inflammatory responses to prevent the onset of cytokine storm. However, further in vitro and in vivo experiments are warranted to validate the current findings with system biology tools. Our current approach provides a new strategy in predicting formulation rationale when developing new dietary supplements.

Keywords: coronavirus, vitamin C, curcumin, glycyrrhizic acid, system biology, inflammatory response, immune response

1. Introduction

Coronaviruses (CoVs) belong to the Coronaviridae virus family and are enveloped, positive-sense RNA viruses [1]. CoVs infect various host species, including humans and other vertebrates. In recent years, novel CoVs emerged periodically in different regions around the globe, such as severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and SARS-CoV-2 in late 2019 [2]. These viruses predominantly cause respiratory and intestinal tract infections and induce various clinical manifestations [3]. Although the pathologies of these virus are not yet completely understood, viral proteins and host factors play key roles in the infection process [4]. A well-coordinated immune response is essential against virus infection. In contrast, an out of control immune response is associated with immunopathogenesis and excessive inflammatory response, which may result in poor outcomes such as severe pulmonary damage and multi-organ failure [5,6]. Due to the challenges of developing antiviral drugs and vaccines, the outbreaks of CoV infections often cause major public health issues [7]. CoV-infected people must rely on their own immune defense to control the progress of infection. These diseases are classified as self-limiting diseases, meaning that an individual’s immune function will determine whether early symptoms will advance into severe acute respiratory tract symptoms (i.e., pneumonia) or recovery from infection.

Phytonutrients are a variety of bioactive non-nutrient plant compounds that exhibit the capacity to alter biochemical reactions and consequently influence human health after ingestion [8,9]. Commonly known phytonutrients in dietary supplements include flavonoids, anthocyanin, carotenoids, polyphenols, triterpenoids and phytosterols, many of which have been reported to play important roles in human health with potential as therapeutic agents [10,11]. It is well-known that adequate intake of nutrients and phytonutrients may help regulate immune function, including enhancing defense and resistance to infection, while maintaining tolerance [12]. Several plant food sources, such as acerola berry (Malpighia glabra L., M. emarginata D.C.), roxburgh rose fruit (Rosa roxburghii Tratt.), camu camu (Myrciaria dubia (Kunth) McVaugh), amla (Phyllanthus emblica L.) and sea buckthorn berry (Hippophae rhamnoides L.) are known as rich sources of vitamin C (VC). VC regulates immunity by enhancing differentiation and proliferation of B- and T-cells, and it is beneficial in preventing and treating respiratory and systemic infections [13,14,15]. VC potentially protects against infection caused by CoVs due to its benefits on immune function [16]. High doses of VC were recommended for prevention of SARS-CoV-2 infections by the Chinese Center for Disease Control and Prevention and Chinese Nutrition Society. Currently, VC is under investigation in a clinical trial for its benefit in patients with severe SARS-CoV-2 infection (https://clinicaltrials.gov/).

Glycyrrhizic acid (GA) is a major phytonutrient found in licorice root (Glycyrrhiza uralensis Fisch. ex DC., G. inflata Bat., G. glabra L.), which is considered an ingredient for both food and medicinal use in China [17]. GA exhibits anti-viral [18], anti-inflammatory [19] and hepatoprotective activities [20]. Traditional Chinese medicine (TCM) treatments for SARS-CoV-2 infection pneumonia were recommended by National Health Commission of China, and licorice root was one of the commonly used TCM herbs [21]. GA has been reported recently for its binding capability with angiotensin-converting enzyme 2 (ACE2) to prevent SARS-CoV-2 infection [22]. Intriguingly, the effect of diammonium glycyrrhizinate combined with vitamin C tablets on common pneumonia infected with SARS-CoV-2 is being tested in clinical trials (http://www.chictr.org.cn/).

Curcumin (CC) and its analogues are the main phytonutrients of turmeric (Curcuma longa L.) and other Curcuma spp., which are widely used around the world as culinary spices, traditional medicine as well as a popular dietary supplement ingredient due to its wide range of health benefits including anti-inflammation [23], anti-cancer [24], cardiovascular regulation [25], respiratory [26] and immune system benefits [27]. In addition, the suppression of multiple cytokines by curcumin suggested that it may be a useful approach in treating Ebola patients against cytokine storm [28]. CC also inhibited aminopeptidase N (APN) which was identified as a cellular receptor for alpha CoV [29].

Since VC, CC and GA are popular in nutrition, and more importantly, they have been used to regulate immune responses and recommended to intervene in CoV infections, a combination of VC, CC and GA (VCG Plus) was proposed for its potential to prevent CoVs infection. In the present study, our objective is to apply system biology techniques to investigate biological processes and pathways that are regulated by VCG Plus, and to illustrate how these biological processes and pathways could be associated with protection against CoV infections.

2. Method

2.1. Gene Target Acquisition and Screening

Comprehensive determination of potential compound–target interaction profiles is a critical step for the system biology analysis [30]. Currently, multiple databases/platforms, such as DrugBank Database, Comparative Toxicogenomics Database (CTD), Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine (TCMIP), were commonly applied to acquire potential targets of small molecular compounds [31,32,33]. DrugBank contains detailed drug, drug-target, drug action and drug interaction information about FDA-approved drugs as well as experimental drugs [34]. CTD provides core information on chemical-gene interactions that are manually curated from scientific literature [35,36]. While TCMIP predicts the potential targets for herbal chemical compounds using MedChem Studio (version 3.0), an efficient drug similarity search tool to identify herbal chemical compounds with high structural similarity (Tanimoto score > 0.8) to known drugs [37]. Basically, the target information in these three databases is complementary, a combination of which could provide relatively comprehensive compound-target interactions. In this work, the target acquisition of VC, CC and GA was conducted separately, using direct text mining of DrugBank, CTD and TCMIP with their chemical names as keywords. The targets of VC and CC from CTD with interaction counts less than 5 were excluded. All acquired targets of VC, CC and GA were limited to Homo sapiens and mapped to UniProt [38] for correction to remove redundant and erroneous ones.

2.2. Hub Target Identification and Protein–Protein Interaction (PPI) Analysis

Hub targets were identified by taking following steps:

(1) Combine the targets of VC, CC and GA and remove the duplicates;

(2) Map them into the CTD website, choose “virus diseases” and “immune system diseases” gene database for comparison, select the overlapping targets for the next analysis;

(3) Map selected targets into STRING (Version 11.0) to perform PPI analysis [39], set the cut-off degree of PPI as high confidence (0.700), and download the information of PPI as TSV file format;

(4) Import the file to Cytoscape software (Version 3.6.1) [40] to analyze the topological parameters of the interactions, select the hub targets whose node degree is greater than the median value. After these steps, STRING and Cytoscape are used subsequently to construct and analyze the PPI network of hub targets. In constructed networks, the targets are represented by nodes while the interactions among them are represented by edges.

2.3. Distribution Analysis of Targets in Tissues/System and Gene Ontology (GO) Enrichment and Analysis

Gene ORGANizer [41] was employed to perform the target-system location analysis. DAVID Bioinformatics Resources 6.8 [42] was applied to perform GO analysis for the hub targets. The biological process, cell component and molecular function were three basic outputs of GO. The cut-off value of the p-value was set to 0.05, and the p-value was adjusted using the Benjamini–Hochberg method. In addition, the analysis of specific GO annotation involved in immune system processes was carried out with ClueGo (Version 2.5.6) [43], a Cytoscape plug-in integrating EBI-Uniport GO annotation database (updated in Mar 2019). Generally, the targets from VC, CC and GA were imported to ClueGo separately and represented by different colors. The visual style of ClueGo analysis was set as “cluster”. The GO term/pathway was added to a specific cluster term if at least 80% of genes in this term is contributed by an individual (phyto-) nutrient. Only terms with a p-value less than 0.05 were presented after two-side hypergenometric test and bonferroni step down adjustment were conducted.

2.4. Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Analysis

KEGG pathway enrichment and analysis were performed on ClueGo integrating with KEGG database (updated in 17 February 2020). The procedures were similar to the immune system process GO term analysis, briefly described below:

(1) import the targets of VC, CC and GA to ClueGo separately, represent by different colors;

(2) set visual style as “cluster”, and set statistical method as two-side hypergenometric test and bonferroni step down adjustment, only pathways with p-value less than 0.05 are shown;

(3) start analysis, download the protein-pathway interactions information in Excel format for analysis. According to KEGG database, pathways are clustered into the following categories: (A) metabolism, (B) genetic information processing, (C) environmental information processing, (D) cellular processes, (E) organismal systems, and (F) human diseases. Finally, the top 15 protein–pathway interactions related to immune and inflammatory responses were extracted and shown.

3. Results

3.1. Hub Target Identification and Analysis

Three public databases were used to mine the potential targets for the three (phyto-) nutrients in VCG Plus. The number of qualified targets identified for VC, CC and GA were 109, 146, and 65, respectively (Supplementary Table S1), and a total of 248 unique targets were identified for the combination of VCG Plus (phyto-) nutrients. Comparing the results with “virus diseases” and “immune system disease” gene data in CTD, it was found that 179 targets existed in both the “virus diseases” and “immune system disease” gene database. These 179 targets were then selected to perform PPI analysis and network topological analysis. As a result, 88 tightly connected targets (hub targets, node degree ≥ 12) were identified for further analysis. Detailed information of the 88 hub targets is shown in Table 1. A Venn diagram (Figure 1A) shows that 13 targets overlap for the combination of VCG Plus (phyto-) nutrients, which include ALB, CASP3, CXCL8, HMOX1, NFKB1, NFKBIA, PTGS2, RELA, TGFB1 NOS2, SOD2, IFNG and TNF. In addition, there are nine overlapping targets for CC and GA, and 22 overlapping targets for VC and CC. Furthermore, the PPI of hub targets was constructed by STRING and they are shown in Figure 1B. The PPI network was assembled by 88 nodes (targets) and 1153 edges (interactions), with clustering coefficients of 0.59 and an average number of neighbors of 26.21. The targets are closely connected, suggesting that they may position in similar biological pathways with similar health benefits.

Table 1.

Hub targets identified for VCG Plus. VCG Plus, the combination of vitamin C, curcumin and glycyrrhizic acid. VC, vitamin C; CC, curcumin; GA, glycyrrhizic acid.

GENE_SYMBOL Name Distribution
EP300 E1A binding protein p300 CC only
VCAM1 vascular cell adhesion molecule 1 CC only
CCN2 cellular communication network factor 2 CC only
MYC MYC proto-oncogene, bHLH transcription factor CC only
VEGFA vascular endothelial growth factor A CC only
ADIPOQ adiponectin, C1Q and collagen domain containing CC only
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta CC only
FN1 fibronectin 1 CC only
ESR1 estrogen receptor 1 CC only
MAPK8 mitogen-activated protein kinase 8 CC only
GSTP1 glutathione S-transferase pi 1 CC only
FOS Fos proto-oncogene, AP-1 transcription factor subunit CC only
AKT1 AKT serine/threonine kinase 1 CC only
IFNB1 interferon beta 1 CC only
MDM2 MDM2 proto-oncogene CC only
CXCL1 C-X-C motif chemokine ligand 1 CC only
CXCL2 C-X-C motif chemokine ligand 2 CC only
PDGFB platelet derived growth factor subunit B CC only
AHR aryl hydrocarbon receptor CC only
CYP2E1 cytochrome P450 family 2 subfamily E member 1 CC only
EGFR epidermal growth factor receptor CC only
EGR1 early growth response 1 CC only
IGF1R insulin like growth factor 1 receptor CC only
BIRC3 baculoviral IAP repeat containing 3 CC only
IGFBP3 insulin like growth factor binding protein 3 CC only
STAT3 signal transducer and activator of transcription 3 CC only
EGF epidermal growth factor CC only
IL18 interleukin 18 CC only
CCND1 cyclin D1 CC only
MMP9 matrix metallopeptidase 9 CC only
BCL2L1 BCL2 like 1 CC only
JUN Jun proto-oncogene, AP-1 transcription factor subunit CC only
IL10 interleukin 10 CC only
HMGB1 high mobility group box 1 CC_GA_intersect
IL6 interleukin 6 CC_GA_intersect
CREB1 cAMP responsive element binding protein 1 CC_GA_intersect
IFNG interferon gamma CC_GA_intersect
BDNF brain derived neurotrophic factor CC_GA_intersect
MMP2 matrix metallopeptidase 2 CC_GA_intersect
CCL2 C-C motif chemokine ligand 2 CC_GA_intersect
CASP9 caspase 9 CC_GA_intersect
AR androgen receptor CC_GA_intersect
CASP8 caspase 8 CC_GA_intersect
SIRT1 silent mating type information regulation 2 homolog 1 GA only
BMP2 bone morphogenetic protein 2 VC only
TIMP1 TIMP metallopeptidase inhibitor 1 VC only
TLR2 toll like receptor 2 VC only
SPP1 secreted phosphoprotein 1 VC only
MMP13 matrix metallopeptidase 13 VC only
NOS3 nitric oxide synthase 3 VC only
TF transferrin VC only
RUNX2 RUNX family transcription factor 2 VC only
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit VC only
CD44 CD44 molecule VC only
HMOX1 heme oxygenase 1 VC_CC_GA_intersect
RELA RELA proto-oncogene, NF-κB subunit VC_CC_GA_intersect
TGFB1 transforming growth factor beta 1 VC_CC_GA_intersect
PTGS2 prostaglandin-endoperoxide synthase 2 VC_CC_GA_intersect
NFKBIA NF-κB inhibitor alpha VC_CC_GA_intersect
NFKB1 nuclear factor kappa B subunit 1 VC_CC_GA_intersect
CXCL8 C-X-C motif chemokine ligand 8 VC_CC_GA_intersect
SOD2 superoxide dismutase 2, mitochondrial VC_CC_GA_intersect
ALB albumin VC_CC_GA_intersect
TNF tumor necrosis factor VC_CC_GA_intersect
NOS2 nitric oxide synthase 2 VC_CC_GA_intersect
CASP3 caspase 3 VC_CC_GA_intersect
PARP1 poly (ADP-ribose) polymerase 1 VC_CC_intersect
CTNNB1 catenin beta 1 VC_CC_intersect
NQO1 NAD(P)H quinone dehydrogenase 1 VC_CC_intersect
NFE2L2 nuclear factor, erythroid 2 like 2 VC_CC_intersect
PPARG peroxisome proliferator activated receptor gamma VC_CC_intersect
IL1B interleukin 1 beta VC_CC_intersect
MAPK3 mitogen-activated protein kinase 3 VC_CC_intersect
MAPK1 mitogen-activated protein kinase 1 VC_CC_intersect
MPO myeloperoxidase VC_CC_intersect
TLR4 toll like receptor 4 VC_CC_intersect
COL1A1 collagen type I alpha 1 chain VC_CC_intersect
AGT angiotensinogen VC_CC_intersect
APP amyloid beta precursor protein VC_CC_intersect
HIF1A hypoxia inducible factor 1 alpha subunit VC_CC_intersect
CDKN1A cyclin dependent kinase inhibitor 1A VC_CC_intersect
IGF1 insulin like growth factor 1 VC_CC_intersect
SOD1 superoxide dismutase 1 VC_CC_intersect
CYP1A1 cytochrome P450 family 1 subfamily A member 1 VC_CC_intersect
BCL2 BCL2, apoptosis regulator VC_CC_intersect
TP53 tumor protein p53 VC_CC_intersect
CAT catalase VC_CC_intersect
ICAM1 intercellular adhesion molecule 1 VC_CC_intersect

Figure 1.

Figure 1

Hub target analysis of VCG Plus. A Venn diagram of hub target distribution in VC, CC and GA, respectively (A). PPI network of 88 hub targets of VCG Plus (B). OmicsBean (http://www.omicsbean.cn/) was employed to draw Figure 1A. Cytoscape software (Version 3.6.1) was employed to draw Figure 1B. In Figure 1B, all the targets are represented by nodes, whereas the interaction between the targets are represented by edges. The node size is proportional to the node degree. The intersect targets of VC, CC and GA are represented by green. VCG Plus, the combination of vitamin C, curcumin and glycyrrhizic acid. VC, vitamin C (group1); CC, curcumin (group 2); GA, glycyrrhizic acid (group 3). PPI, protein-protein interaction.

3.2. Enrichment and Analysis of Target Distribution in Tissues and Systems

We analyzed the system distribution of 88 targets to better explore the potential function on a system level. The top 10 systems are shown in Figure 2A. The respiratory system was found as the most significant location which contained 78 targets, followed by the urinary (74 targets), cardiovascular (84 targets), digestive (83 targets) and immune systems (64 targets). In addition, the tissue distribution of the targets for each (phyto-) nutrient was analyzed. The top three significant tissues of each individual compound were shown in Figure 2B. It is interesting that targets of these (phyto-) nutrients are all enriched in the heart. However, targets of CC are also enriched in the lung and liver, while targets of GA are enriched in the intestine and large intestine, and targets of VC are enriched in the peripheral nerves and coagulation system.

Figure 2.

Figure 2

Distribution analysis of targets in tissues and systems. The bubble plots were made using JMP software 14.2.0 (SAS institute Inc. USA). Distribution of targets of VCG Plus in system (A), distribution of targets of VC, CC and GA in tissues (B). In Figure 2A, the bubble size is proportional to the targets number, and the shade of bubble is inversely proportional to the p-value. In Figure 2B, the bubble size is proportional to the targets number. The targets distribution of VC is represented by blue bubble, CC is represented by red bubble, and GA are represented by green bubble. VC, vitamin C; CC, curcumin; GA, glycyrrhizic acid.

CoV infections may lead to inflammation and alter immune responses, which are generally associated with the respiratory and immune systems [4,44]. Some digestive and cardiovascular events, such as diarrhea [45], heart palpitations [46] and abnormal coagulation parameters [47] were observed in clinical studies, suggesting that coronavirus infection may result in systemic damage. In this sense, the VCG Plus targets could cover most systems and tissues, indicating the potential to systematically intervene in the process of virus infection. The results also indicate that VCG Plus may have the potential to improve systematic immune and inflammatory responses caused by virus infections.

3.3. Enrichment and Analysis of GO Term

All enriched GO terms are available in Supplementary Table S2. The top 10 significant terms in biological process, molecular function and cellular component categories, respectively, are shown in Figure 3. VCG Plus is active in regulating transcription from RNA polymerase II promoter and transcription of DNA-templated via binding of transcription factor and chromatin. VCG Plus regulates the apoptotic process, nitric oxide biosynthetic process and lipopolysaccharide-mediated signaling pathway through cytokine activity, enzyme binding and/or protein binding. The biological process result for responding to hypoxia is worth mentioning, since a decline in oxygen saturation is commonly observed in SARS-CoV-2 infected patients [45]. The hypoxic response is a systemic process that regulates multiple cellular activities to maintain homeostasis under hypoxic condition [48]. In the present work, we note that both VC and CC could act on hypoxia inducible factor 1 alpha subunit (HIF-1A), suggesting their potential benefits on maintaining homeostasis under hypoxic conditions.

Figure 3.

Figure 3

Top 10 gene ontology (GO) terms of biologic process, molecular function and cellular component, respectively. The bubble plot was made using JMP software 14.2.0 (SAS institute Inc. USA). The bubble size is proportional to the targets number, and the shade of bubble is inversely proportional to the p-value.

In addition, GO analysis of biological processes related to the immune system was performed using ClueGo. ClueGo was used to generate the targets-processes network of VC, CC and GA and shown as clusters, so that the role of each nutrient contributing to pathway regulation could be visualized (Figure 4). As a result, nine significant immune system processes were obtained, including differentiations of macrophage, leukocyte, myeloid cell and myeloid leukocyte, activation of macrophage and T-cell, T cell lineage commitment and hemopoiesis. These results suggest that VCG Plus may enhance immunity by modulating the regulation of immune cell differentiation and activation.

Figure 4.

Figure 4

Target immune-related biologic process network. The network was constructed by ClueGo (Latest Version 2.5.6), integrating immune process EBI-Uniport GO annotation database. Only pathways with p < 0.05 are shown. The targets and biologic processes are represented by nodes while the interactions among them are represented by edges. Contribution of VC (vitamin c) in targets and pathways is represented by red, while CC (curcumin) is represented by blue, and GA (glycyrrhizic acid) is represented by green.

3.4. KEGG Pathway Enrichment and Analysis

All 88 identified targets were imported to ClueGo for KEGG pathway enrichment, resulting in 110 statistically significant pathways (Supplementary Table S3). According to the KEGG database, the obtained pathways are mainly concentrated on categories of signal transduction involved in environmental information processes, immune systems involved in organismal systems, infectious diseases involved in human diseases and other pathways. The top 15 pathways which are closely related to immunity, inflammation and RNA virus infections, along with effective target interactions were demonstrated in Figure 5. PI3K-AKT signaling pathway is associated with the most targets (30 targets), followed by TNF signaling pathway (25 targets), HIF-1 signaling pathway (23 targets), IL-17 signaling pathway (22 targets), NOD-like receptor signaling pathway (22 targets), Influenza A (21 targets), FoxO signaling pathway (20 targets), Toll-like receptor signaling pathway (19 targets), NF-κB signaling pathway (17 targets) and T helper (Th)17 cell differentiation (16 targets). Other pathways which belong to the immune system include T-cell receptor, Th17 cell differentiation and C-type lectin receptor signaling, and inflammation-related pathways including JAK-STAT signaling and apoptosis are also shown.

Figure 5.

Figure 5

Target KEGG pathways network of VCG Plus. The network was constructed by ClueGo (Latest Version 2.5.6), integrating the latest KEGG pathway database. The targets and pathways are represented by nodes while the interactions among them are represented by edges. Contribution of VC (vitamin c) in targets and pathways is represented by red, while CC (curcumin) is represented by blue, and GA (glycyrrhizic acid) is represented by green.

4. Discussion

The interaction between CoV spike (S) protein and its receptor is the primary determinant for such virions attachment to human cells [49]. Multiple peptidases have been well described as CoV cellular receptors, including APN as the receptor for alpha CoV, angiotensin-converting enzyme 2 (ACE2) as the receptor for SARS-CoV and dipeptidyl-peptidase 4 (DPP4) as the receptor for MERS-CoV [1]. Inhibitors of S protein binding to receptor is a strategy for preventing and treating infection [7,50]. Although our data did not show that VCG Plus (phyto-) nutrients act on CoV cellular receptor, the potential capability of GA binding to ACE2 was reported recently [22]. Moreover, CC has been reported as the inhibitor of APN with potential to be a cancer chemoprevention agent [29]. The interactions between CC and APN, and GA and ACE2 were not included in our current analysis, mainly due to our strict rules for target screening. Through Venn analysis of targets from VCG Plus, silent mating type information regulation 2 homolog 1 (SIRT1) was found to only interact with GA. SIRT 1 belongs to the sirtuin family which contains seven proteins (SIRT1-7) that are class III NAD+-dependent histone deacetylases (HDACs) [51]. It is interesting that SIRT1 has been shown to play both pro-viral and anti-viral roles, depending on the type of virus. The SIRT1 inhibitor showed a suppressive effect on hepatitis B virus (HBV) replication [51,52], while the SIRT1 activator showed a suppressive effect on human T-cell leukemia virus type 1 (HTLV-1) [53] and MERS-CoV [54]. Han [55] found that SIRT1 inhibited viral RNA transcription and translation in enterovirus 71 (EV 71, a RNA virus)-infected human rhabdomyosarcoma (RD) cells. Based on these results, it is possible that SIRT 1 could be an antiviral for RNA virus infections like MERS-CoV and EV 71. Containing the key phytochemical GA, licorice is generally associated with detoxication in TCM [56], and exhibits antiviral effect [57,58,59]. Others have found that GA activates SIRT1 in diabetic db/db mice [60] and increases the expression of SIRT1 in renal tubular epithelial cell line [61]. Hence, it is speculated that GA may exert anti-CoV effects via regulating SIRT 1 protein. However, further experimental research is needed to clarify the antivirus mechanism of GA as well as the role of SIRT1 in various CoV infections.

The innate immune system is the first line of defense against virus infection. A rapid and well-coordinated innate immune response to sense invading viruses, and subsequent signal transduction pathways targeted to inhibit infection [62]. During a viral infection, host pathogen-recognition receptors (PRRs) initially sensitized by viral pathogen-associated molecular patterns and cascades of signaling pathways are activated to produce type 1 interferons (IFNs). IFNs are the prominent cytokines in innate immune response, and are thought to enhance the release of antiviral proteins for the protection of uninfected cells [5,63]. CoV can be sensed by three types of PRR, including Toll-like receptors, retinoic acid-inducible gene I (RIG-I)-like receptors, and nucleotide-binding and oligomerization domain (NOD)-like receptors [4]. Sometimes, accessory proteins of SARS-CoV and MERS-CoV can interfere with PRRs, antagonize IFNs’ response and evade the immune response. The delayed IFNs’ response may result in uncontrolled inflammatory response [64,65]. In our present study, the results demonstrate the involvement of PRR signaling-related pathways including NOD-like receptors, Toll-like receptors (Figure 5) and RIG-I like receptors signaling (Supplementary Table S3) pathways in the biological functions of VCG Plus, as well as the IFNs (IFNG, IFNB1 in Table 1). Previous studies have revealed that CC significantly stimulated the production of IFN-β (IFNB1) in mice infected with influenza A virus (IAV), resulting in the increased survival rate and improvement of pulmonary histopathological changes [66]. Similarly, VC improved the production of IFN α/β (IFNA1/B1), activated anti-viral immune responses and remarkably increased the survival rate of VC-depleted mice infected with IAV [67,68]. In addition, multiple groups have demonstrated that GA improves IFN-γ (IFNG) production and ameliorates immune function [69,70,71]. These results indicate that VCG Plus may be beneficial in regulating innate immune response against invading viruses, through regulating NOD-like, Toll-like receptor signaling pathways, and promoting the production of IFNs.

T-cells, including CD4+ cells, and CD8+ cells play an antiviral role not only by combating against virions but also restricting the development of autoimmunity or overwhelming inflammation [4]. CD4+ cells promote the production of virus-specific antibodies via activating T-dependent B-cells, whereas CD8+ cells kill viral infected cells [72]. However, some CoVs are thought to induce T-cell apoptosis by the activation of apoptosis pathways [73], while depletion of CD4+ cells in later stages is associated with immune-mediated interstitial pneumonitis and delayed clearance of pathogen [74]. In SARS-CoV-2 infected patients, both the counts of CD4 + cells and CD8+ cells in severe pneumonia patients were lower than non-severe patients [75]. Similar results were observed in SARS-CoV infected patients [76,77]. In our current study, the significant interactions of VCG Plus related to immune cell differentiation and activation pathways were observed (Figure 4). The VCG Plus (phyto-) nutrients in this combination can co-regulate T-cell activation and other related biological processes by acting on different targets, suggesting the existence of a potential synergy. The literature has shown that VCG Plus (phyto-) nutrients positively regulate T-cells. For instance, VC positively influences lymphocyte development and function, and enhances T-cell proliferation and T-cell function [14,78]. CC could target regulatory T-cells and convert them into CD4+ Th1 cells to process anti-tumor effects [79,80], and improve the imbalance of Th1/Th2 subsets to process anti-inflammatory and anti-autoimmune effects [27,81]. GA showed anti-allergic effect by restoring the imbalance of Th1/Th2 subsets [82,83]. These results suggest that VCG Plus could promote the proliferation of Th1 cells and the production of virus-specific antibodies to compete CoV infections, and simultaneously regulate the Th1/Th2 subsets to prevent autoimmune and excessive inflammatory response in the later stage of infection.

A cytokine storm, the massive overproduction of cytokines by the immune system, often appears in the terminal stage of some viral diseases (SARS, MERS, SARS-CoV-2). It is partially responsible for high fatality rates in patients infected with viruses [3]. In a cytokine storm, numerous pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α, and inflammatory chemokines CCL3, CCL5, CCL2, and CXCL10 are released, leading to hypotension, hemorrhage, and eventually multiorgan failure [84]. MAPKs signaling [85], NF-κB signaling [86,87], TNF signaling [88] and PI3K/AKT signaling pathways [85,89], play important roles in mediating CoV infection-induced inflammatory responses. As a matter of fact, the anti-inflammatory effects of VC, CC and GA have been well documented. VC decreases IL-4, IL-6 and IL-8 level via inhibition of NF-κB signaling pathway in concanavalin A- induced liver injury mice [90]. Many studies have shown that CC presents anti-inflammatory function via NF-κB signaling [91,92], PI3K/AKT signaling [93], MAPK signaling [66] and TLRs signaling pathways [94]. In addition, GA alleviated inflammation via NF-kB and p38/ERK pathways in the reduction in multiple cytokines, including IL-6, TNF-α, IL-8, IL-1β and HMGB1 [95]. Consistently, the pathways mentioned above were successfully enriched and demonstrated in our result (Figure 5). Together with the evidence from the literature, our findings suggest that this combination may prevent the onset of cytokine storm.

VC is an essential nutrient derived from plant sources, GA is derived from licorice, which is the most popular herb in TCM and other traditional medicine, and CC is derived from turmeric which is the most popular botanical source for Ayurveda medicine and culinary herbs. The combination of these three (phyto-) nutrients has not been reported previously, despite the single use of each ingredient has been widely studied. In this study, we first collected gene targets of VC, CC and GA, followed by target enrichment and analysis including distribution in tissues and systems, GO function and KEGG pathways. As target acquisition is the critical step for the whole analysis, an optimized strategy was used in our study. Briefly, we compared the targets from multiple databases, set high, reliable cut-off values and reviewed the text description of interactions, to ensure the high credibility of targets. In addition, we narrowed down the range by mapping to “immune system disease” and “virus diseases” related gene databases in CTD, to ensure a more focused analysis. After step by step system biology analysis, combined with up to date molecular mechanism investigations of CoV infections, our results suggest VCG Plus may regulate immune and inflammatory responses to prevent CoV infections by acting on multiple targets and pathways. Regulating NOD-like and Toll-like receptor signaling, promoting IFNs production, inhibition of PI3K/AKT, NF-κB and MAPK signaling, and activating and balancing T cells are the main functional mechanisms identified. In addition to the function of the individual (phyto-) nutrients in the VCG plus, they appear to be complementary and synergistic by modulating a variety of targets through similar or different signal pathways.

There are limitations of the current investigation. For example, the pathogenic mechanism of CoV infection is not clearly understood yet, and the study of specific protections against CoV infections of VC, CC and GA was very limited. We only conducted the analysis on our best knowledge at the time. We started the analysis from known potential targets of VCG Plus, followed by enrichment analysis of biological processes and pathways which were generally associated with the immune system and viral infection. Based on the recent advances in the knowledge of CoV infection pathogenic mechanism and the findings from our analysis, VCG Plus regulates CoV infection pathways and were highlighted in our discussion. The results may not comprehensively illustrate how this combination would help immune system defense to CoV infections, but it demonstrates the potential of VCG Plus. In addition, the dose and route of administration of VCG or ADME were not taken into consideration in the current work. However, technologies to enhance bioavailability have been widely studied and indicated that advanced formulation processes could minimize these issues. Further in vitro mechanistic and preclinical studies are warranted in order to verify the directional prediction obtained from our current analysis.

5. Conclusions

In summary, since no specific therapy for CoV infections is available, any potential way of protecting against CoV infections is worth studying and discussing. This paper investigated the potential protective effect of VCG Plus against CoV infections using systems biology. Our results suggest that VCG Plus is predicted to be helpful in regulating immune response against CoV infections and inhibiting excessive inflammatory response to prevent the onset of cytokine storm. However, further in vitro/in vivo experiments are warranted for validation. The analytical approach in this study provides a new thinking process to support the formulation strategy for the development of new dietary supplements with potential immune benefits.

Acknowledgments

This study did not receive any specific grant from funding agencies in public, commercial, or not-for-profit sectors.

Supplementary Materials

The following are available online at https://www.mdpi.com/2072-6643/12/4/1193/s1, Table S1: Acquired targets of VC (vitamin C), CC (curcumin) and GA (glycyrrhizic acid)., Table S2: GO (Gene ontology) enrichment results from DAVID Bioinformatics Resources 6.8 (https://david.ncifcrf.gov/tools.jsp), including biological process (BP), cell component (CC) and molecular function (MF). Table S3: KEGG pathways enrichment results from ClueGo (integrates the latest KEGG database).

Author Contributions

Conceptualization, L.C. and J.D.; methodology, L.C.; validation, C.H., M.H. and J.D.; formal analysis, L.C.; investigation, L.C., X.Z., L.Z. and J.K.; resources, X.Z., L.Z. and J.K.; data curation, L.C.; writing—original draft preparation, L.C.; writing—review and editing, L.C., C.H., M.H. and J.D.; supervision, J.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

  • 1.Fehr A.R., Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier H.J., Bickerton E., Britton P., editors. Coronaviruses. Volume 1282. Springer New York; New York, NY, USA: 2015. pp. 1–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Xu B., Kraemer M.U.G., Xu B., Gutierrez B., Mekaru S., Sewalk K., Loskill A., Wang L., Cohn E., Hill S., et al. Open access epidemiological data from the COVID-19 outbreak. Lancet Infect. Dis. 2020 doi: 10.1016/S1473-3099(20)30119-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Channappanavar R., Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017;39:529–539. doi: 10.1007/s00281-017-0629-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., et al. Coronavirus infections and immune responses. J. Med. Virol. 2020;92:424–432. doi: 10.1002/jmv.25685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Zheng J., Perlman S. Immune responses in influenza A virus and human coronavirus infections: An ongoing battle between the virus and host. Curr. Opin. Virol. 2018;28:43–52. doi: 10.1016/j.coviro.2017.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020:105924. doi: 10.1016/j.ijantimicag.2020.105924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zumla A., Chan J.F.W., Azhar E.I., Hui D.S.C., Yuen K.-Y. Coronaviruses—Drug discovery and therapeutic options. Nat. Rev. Drug Discov. 2016;15:327–347. doi: 10.1038/nrd.2015.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Liu R.H. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am. J. Clin. Nutr. 2003;78:517S–520S. doi: 10.1093/ajcn/78.3.517S. [DOI] [PubMed] [Google Scholar]
  • 9.Chang S.K., Alasalvar C., Shahidi F. Review of dried fruits: Phytochemicals, antioxidant efficacies, and health benefits. J. Funct. Foods. 2016;21:113–132. doi: 10.1016/j.jff.2015.11.034. [DOI] [Google Scholar]
  • 10.Oh J., Wall E.H., Bravo D.M., Hristov A.N. Host-mediated effects of phytonutrients in ruminants: A review. J. Dairy Sci. 2017;100:5974–5983. doi: 10.3168/jds.2016-12341. [DOI] [PubMed] [Google Scholar]
  • 11.Gupta C., Prakash D. Phytonutrients as therapeutic agents. J. Complement. Integr. Med. 2014;11:151–169. doi: 10.1515/jcim-2013-0021. [DOI] [PubMed] [Google Scholar]
  • 12.Wu D., Lewis E.D., Pae M., Meydani S.N. Nutritional Modulation of Immune Function: Analysis of Evidence, Mechanisms, and Clinical Relevance. Front. Immunol. 2019;9 doi: 10.3389/fimmu.2018.03160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wintergerst E.S., Maggini S., Hornig D.H. Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Ann. Nutr. Metab. 2006;50:85–94. doi: 10.1159/000090495. [DOI] [PubMed] [Google Scholar]
  • 14.Ang A., Pullar J.M., Currie M.J., Vissers M.C.M. Vitamin C and immune cell function in inflammation and cancer. Biochem. Soc. Trans. 2018;46:1147–1159. doi: 10.1042/BST20180169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Carr A.C., Maggini S. Vitamin C and Immune Function. Nutrients. 2017;9:1211. doi: 10.3390/nu9111211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhang L., Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol. 2020;92:479–490. doi: 10.1002/jmv.25707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hu C. Chapter 21—Historical Change of Raw Materials and Claims of Health Food Regulations in China. In: Bagchi D., editor. Nutraceutical and Functional Food Regulations in the United States and Around the World. 2nd ed. Academic Press; San Diego, CA, USA: 2014. pp. 363–388. [Google Scholar]
  • 18.Pompei R., Laconi S., Ingianni A. Antiviral properties of glycyrrhizic acid and its semisynthetic derivatives. Mini. Rev. Med. Chem. 2009;9:996–1001. doi: 10.2174/138955709788681636. [DOI] [PubMed] [Google Scholar]
  • 19.Ming L.J., Yin A.C.Y. Therapeutic effects of glycyrrhizic acid. Nat. Prod. Commun. 2013;8:415–418. doi: 10.1177/1934578X1300800335. [DOI] [PubMed] [Google Scholar]
  • 20.Li J., Cao H., Liu P., Cheng G., Sun M. Glycyrrhizic acid in the treatment of liver diseases: Literature review. Biomed. Res. Int. 2014;2014:872139. doi: 10.1155/2014/872139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Luo H., Tang Q., Shang Y., Liang S., Yang M., Robinson N., Liu J. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs. Chin. J. Integr. Med. 2020;26:243–250. doi: 10.1007/s11655-020-3192-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chen H., Du Q. Potential natural compounds for preventing 2019-nCoV infection. Preprints. 2020:2020010358. doi: 10.20944/preprints202001.0358.v3. [DOI] [Google Scholar]
  • 23.Deguchi A. Curcumin targets in inflammation and cancer. Endocr. Metab. Immune Disord. Drug Targets. 2015;15:88–96. doi: 10.2174/1871530315666150316120458. [DOI] [PubMed] [Google Scholar]
  • 24.Pulido-Moran M., Moreno-Fernandez J., Ramirez-Tortosa C., Ramirez-Tortosa M. Curcumin and Health. Molecules. 2016;21:264. doi: 10.3390/molecules21030264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kim Y., Clifton P. Curcumin, Cardiometabolic Health and Dementia. Int. J. Environ. Res. Public Health. 2018;15:2093. doi: 10.3390/ijerph15102093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lelli D., Sahebkar A., Johnston T.P., Pedone C. Curcumin use in pulmonary diseases: State of the art and future perspectives. Pharmacol. Res. 2017;115:133–148. doi: 10.1016/j.phrs.2016.11.017. [DOI] [PubMed] [Google Scholar]
  • 27.Bright J.J. Curcumin and autoimmune disease. Adv. Exp. Med. Biol. 2007;595:425–451. doi: 10.1007/978-0-387-46401-5_19. [DOI] [PubMed] [Google Scholar]
  • 28.Sordillo P.P., Helson L. Curcumin Suppression of Cytokine Release and Cytokine Storm. A Potential Therapy for Patients with Ebola and Other Severe Viral Infections. In Vivo. 2015;29:1–4. [PubMed] [Google Scholar]
  • 29.Bauvois B., Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects. Med. Res. Rev. 2006;26:88–130. doi: 10.1002/med.20044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Yadav B.S., Tripathi V. Recent Advances in the System Biology-based Target Identification and Drug Discovery. CTMC. 2018;18:1737–1744. doi: 10.2174/1568026618666181025112344. [DOI] [PubMed] [Google Scholar]
  • 31.Zhang W., Huai Y., Miao Z., Qian A., Wang Y. Systems Pharmacology for Investigation of the Mechanisms of Action of Traditional Chinese Medicine in Drug Discovery. Front. Pharmacol. 2019;10:743. doi: 10.3389/fphar.2019.00743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Chen L., Hu C., Hood M., Kan J., Gan X., Zhang X., Zhang Y., Du J. An Integrated Approach Exploring the Synergistic Mechanism of Herbal Pairs in a Botanical Dietary Supplement: A Case Study of a Liver Protection Health Food. Int. J. Genom. 2020;2020:1–14. doi: 10.1155/2020/9054192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Yue S.-J., Liu J., Feng W.-W., Zhang F.-L., Chen J.-X., Xin L.-T., Peng C., Guan H.-S., Wang C.-Y., Yan D. System Pharmacology-Based Dissection of the Synergistic Mechanism of Huangqi and Huanglian for Diabetes Mellitus. Front. Pharmacol. 2017;8 doi: 10.3389/fphar.2017.00694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wishart D.S., Feunang Y.D., Guo A.C., Lo E.J., Marcu A., Grant J.R., Sajed T., Johnson D., Li C., Sayeeda Z., et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–D1082. doi: 10.1093/nar/gkx1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Davis A.P., Wiegers T.C., Johnson R.J., Lay J.M., Lennon-Hopkins K., Saraceni-Richards C., Sciaky D., Murphy C.G., Mattingly C.J. Text Mining Effectively Scores and Ranks the Literature for Improving Chemical-Gene-Disease Curation at the Comparative Toxicogenomics Database. PLoS ONE. 2013;8:e58201. doi: 10.1371/journal.pone.0058201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Davis A.P., Grondin C.J., Johnson R.J., Sciaky D., McMorran R., Wiegers J., Wiegers T.C., Mattingly C.J. The Comparative Toxicogenomics Database: Update 2019. Nucleic Acids Res. 2019;47:D948–D954. doi: 10.1093/nar/gky868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Xu H.-Y., Zhang Y.-Q., Liu Z.-M., Chen T., Lv C.-Y., Tang S.-H., Zhang X.-B., Zhang W., Li Z.-Y., Zhou R.-R., et al. ETCM: An encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019;47:D976–D982. doi: 10.1093/nar/gky987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wu C.H. The Universal Protein Resource (UniProt): An expanding universe of protein information. Nucleic Acids Res. 2006;34:D187–D191. doi: 10.1093/nar/gkj161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Szklarczyk D., Gable A.L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., Simonovic M., Doncheva N.T., Morris J.H., Bork P., et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–D613. doi: 10.1093/nar/gky1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Su G., Morris J.H., Demchak B., Bader G.D. Biological Network Exploration with Cytoscape 3. Curr. Protoc. Bioinform. 2014;47:8.13.1–8.13.24. doi: 10.1002/0471250953.bi0813s47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Gokhman D., Kelman G., Amartely A., Gershon G., Tsur S., Carmel L. Gene ORGANizer: Linking genes to the organs they affect. Nucleic Acids Res. 2017;45:W138–W145. doi: 10.1093/nar/gkx302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44–57. doi: 10.1038/nprot.2008.211. [DOI] [PubMed] [Google Scholar]
  • 43.Bindea G., Mlecnik B., Hackl H., Charoentong P., Tosolini M., Kirilovsky A., Fridman W.-H., Pagès F., Trajanoski Z., Galon J. ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091–1093. doi: 10.1093/bioinformatics/btp101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia: MERS, SARS and coronaviruses. Respirology. 2018;23:130–137. doi: 10.1111/resp.13196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Kui L., Fang Y.-Y., Deng Y., Liu W., Wang M.-F., Ma J.-P., Xiao W., Wang Y.-N., Zhong M.-H., Li C.-H., et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl.) 2020 doi: 10.1097/CM9.0000000000000744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Tang N., Li D., Wang X., Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020 doi: 10.1111/jth.14768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Nakayama K., Kataoka N. Regulation of Gene Expression under Hypoxic Conditions. Int. J. Mol. Sci. 2019;20:3278. doi: 10.3390/ijms20133278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Cong Y., Ren X. Coronavirus entry and release in polarized epithelial cells: A review: Polarized infection of coronaviruses. Rev. Med. Virol. 2014;24:308–315. doi: 10.1002/rmv.1792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yeung K.-S., Yamanaka G.A., Meanwell N.A. Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Med. Res. Rev. 2006;26:414–433. doi: 10.1002/med.20055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Li W.-Y., Ren J.-H., Tao N.-N., Ran L.-K., Chen X., Zhou H.-Z., Liu B., Li X.-S., Huang A.-L., Chen J. The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo. Arch. Virol. 2016;161:621–630. doi: 10.1007/s00705-015-2712-8. [DOI] [PubMed] [Google Scholar]
  • 52.Deng J.-J., Kong K.-Y.E., Gao W.-W., Tang H.-M.V., Chaudhary V., Cheng Y., Zhou J., Chan C.-P., Wong D.K.-H., Yuen M.-F., et al. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. Biochim. Biophys. Acta (BBA)—Gene Regul. Mech. 2017;1860:491–501. doi: 10.1016/j.bbagrm.2017.02.007. [DOI] [PubMed] [Google Scholar]
  • 53.Tang H.-M.V., Gao W.-W., Chan C.-P., Cheng Y., Deng J.-J., Yuen K.-S., Iha H., Jin D.-Y. SIRT1 Suppresses Human T-Cell Leukemia Virus Type 1 Transcription. J. Virol. 2015;89:8623–8631. doi: 10.1128/JVI.01229-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lin S.-C., Ho C.-T., Chuo W.-H., Li S., Wang T.T., Lin C.-C. Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect. Dis. 2017;17 doi: 10.1186/s12879-017-2253-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Han Y., Wang L., Cui J., Song Y., Luo Z., Chen J., Xiong Y., Zhang Q., Liu F., Ho W., et al. SIRT1 inhibits EV71 genome replication and RNA translation by interfering with the viral polymerase and 5′UTR RNA. J. Cell Sci. 2016;129:4534–4547. doi: 10.1242/jcs.193698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Saito K. Studies on glycyrrhizin, an active principle of radix liquiritine. (3.) on the mechanism of detoxicating action. Gunma J. Med. Sci. 1964;13:275–282. [PubMed] [Google Scholar]
  • 57.Pu J.-Y., He L., Wu S.-Y., Zhang P., Huang X. Anti-virus research of triterpenoids in licorice. Bing Du Xue Bao. 2013;29:673–679. [PubMed] [Google Scholar]
  • 58.Wang J., Chen X., Wang W., Zhang Y., Yang Z., Jin Y., Ge H.M., Li E., Yang G. Glycyrrhizic acid as the antiviral component of Glycyrrhiza uralensis Fisch. against coxsackievirus A16 and enterovirus 71 of hand foot and mouth disease. J. Ethnopharmacol. 2013;147:114–121. doi: 10.1016/j.jep.2013.02.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Feng Yeh C., Wang K.C., Chiang L.C., Shieh D.E., Yen M.H., San Chang J. Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. J. Ethnopharmacol. 2013;148:466–473. doi: 10.1016/j.jep.2013.04.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Hou S., Zhang T., Li Y., Guo F., Jin X. Glycyrrhizic Acid Prevents Diabetic Nephropathy by Activating AMPK/SIRT1/PGC-1 α Signaling in db/db Mice. J. Diabetes Res. 2017;2017:1–10. doi: 10.1155/2017/2865912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Hou S., Zheng F., Li Y., Gao L., Zhang J. The Protective Effect of Glycyrrhizic Acid on Renal Tubular Epithelial Cell Injury Induced by High Glucose. Int. J. Mol. Sci. 2014;15:15026–15043. doi: 10.3390/ijms150915026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Nelemans T., Kikkert M. Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections. Viruses. 2019;11:961. doi: 10.3390/v11100961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K., Perlman S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181–193. doi: 10.1016/j.chom.2016.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Shokri S., Mahmoudvand S., Taherkhani R., Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J. Cell. Physiol. 2019;234:2143–2151. doi: 10.1002/jcp.27155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Peiris M. Pathogenesis of avian flu H5N1 and SARS. Novartis Found. Symp. 2006;279:56–219. [PubMed] [Google Scholar]
  • 66.Dai J., Gu L., Su Y., Wang Q., Zhao Y., Chen X., Deng H., Li W., Wang G., Li K. Inhibition of curcumin on influenza A virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways. Int. Immunopharmacol. 2018;54:177–187. doi: 10.1016/j.intimp.2017.11.009. [DOI] [PubMed] [Google Scholar]
  • 67.Kim Y., Kim H., Bae S., Choi J., Lim S.Y., Lee N., Kong J.M., Hwang Y.-I., Kang J.S., Lee W.J. Vitamin C Is an Essential Factor on the Anti-viral Immune Responses through the Production of Interferon-α/β at the Initial Stage of Influenza A Virus (H3N2) Infection. Immune Netw. 2013;13:70–74. doi: 10.4110/in.2013.13.2.70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Kim H., Jang M., Kim Y., Choi J., Jeon J., Kim J., Hwang Y.-I., Kang J.S., Lee W.J. Red ginseng and vitamin C increase immune cell activity and decrease lung inflammation induced by influenza A virus/H1N1 infection. J. Pharm. Pharmacol. 2016;68:406–420. doi: 10.1111/jphp.12529. [DOI] [PubMed] [Google Scholar]
  • 69.Ram A., Mabalirajan U., Das M., Bhattacharya I., Dinda A.K., Gangal S.V., Ghosh B. Glycyrrhizin alleviates experimental allergic asthma in mice. Int. Immunopharmacol. 2006;6:1468–1477. doi: 10.1016/j.intimp.2006.04.020. [DOI] [PubMed] [Google Scholar]
  • 70.Wang Y., Chai J., Sun M., He W., Hu X., Zou W., Li H., Lu Y., Xie C. Glycyrrhizinic acid modulates the immunity of MRL/lpr mice and related mechanism. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33:305–309. [PubMed] [Google Scholar]
  • 71.Ma C., Ma Z., Liao X., Liu J., Fu Q., Ma S. Immunoregulatory effects of glycyrrhizic acid exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3+ regulatory T cells in ovalbumin-sensitized mice. J. Ethnopharmacol. 2013;148:755–762. doi: 10.1016/j.jep.2013.04.021. [DOI] [PubMed] [Google Scholar]
  • 72.Cecere T.E., Todd S.M., Leroith T. Regulatory T cells in arterivirus and coronavirus infections: Do they protect against disease or enhance it? Viruses. 2012;4:833–846. doi: 10.3390/v4050833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Chu H., Zhou J., Wong B.H.-Y., Li C., Chan J.F.-W., Cheng Z.-S., Yang D., Wang D., Lee A.C.-Y., Li C., et al. Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways. J. Infect. Dis. 2016;213:904–914. doi: 10.1093/infdis/jiv380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Chen J., Lau Y.F., Lamirande E.W., Paddock C.D., Bartlett J.H., Zaki S.R., Subbarao K. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J. Virol. 2010;84:1289–1301. doi: 10.1128/JVI.01281-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Zheng Y., Huang Z., Ying G., Zhang X., Ye W., Hu Z., Hu C., Wei H., Zeng Y., Chi Y., et al. Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. Preprints. 2020 doi: 10.2139/ssrn.3555267. [DOI] [Google Scholar]
  • 76.National Research Project For SARS Beijing Group Beijing 100020 China Dynamic changes of T-lymphocytes and immunoglobulins in patients with severe acute respiratory syndrome. Zhonghua Yi Xue Za Zhi. 2003;83:1014–1017. [PubMed] [Google Scholar]
  • 77.Cui W., Fan Y., Wu W., Zhang F., Wang J., Ni A. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin. Infect. Dis. 2003;37:857–859. doi: 10.1086/378587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Van Gorkom G.N.Y., Klein Wolterink R.G.J., Van Elssen C.H.M.J., Wieten L., Germeraad W.T.V., Bos G.M.J. Influence of Vitamin C on Lymphocytes: An Overview. Antioxidants (Basel) 2018;7:41. doi: 10.3390/antiox7030041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Shafabakhsh R., Pourhanifeh M.H., Mirzaei H.R., Sahebkar A., Asemi Z., Mirzaei H. Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy. Pharmacol. Res. 2019;147:104353. doi: 10.1016/j.phrs.2019.104353. [DOI] [PubMed] [Google Scholar]
  • 80.Zou J.Y., Su C.H., Luo H.H., Lei Y.Y., Zeng B., Zhu H.S., Chen Z.G. Curcumin converts Foxp3+ regulatory T cells to T helper 1 cells in patients with lung cancer. J. Cell. Biochem. 2018;119:1420–1428. doi: 10.1002/jcb.26302. [DOI] [PubMed] [Google Scholar]
  • 81.Rahimi K., Ahmadi A., Hassanzadeh K., Soleimani Z., Sathyapalan T., Mohammadi A., Sahebkar A. Targeting the balance of T helper cell responses by curcumin in inflammatory and autoimmune states. Autoimmun. Rev. 2019;18:738–748. doi: 10.1016/j.autrev.2019.05.012. [DOI] [PubMed] [Google Scholar]
  • 82.Han S., Sun L., He F., Che H. Anti-allergic activity of glycyrrhizic acid on IgE-mediated allergic reaction by regulation of allergy-related immune cells. Sci. Rep. 2017;7:7222. doi: 10.1038/s41598-017-07833-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Wu Q., Tang Y., Hu X., Wang Q., Lei W., Zhou L., Huang J. Regulation of Th1/Th2 balance through OX40/OX40L signalling by glycyrrhizic acid in a murine model of asthma. Respirology. 2016;21:102–111. doi: 10.1111/resp.12655. [DOI] [PubMed] [Google Scholar]
  • 84.Lau S.K.P., Lau C.C.Y., Chan K.-H., Li C.P.Y., Chen H., Jin D.-Y., Chan J.F.W., Woo P.C.Y., Yuen K.-Y. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment. J. Gen. Virol. 2013;94:2679–2690. doi: 10.1099/vir.0.055533-0. [DOI] [PubMed] [Google Scholar]
  • 85.Kindrachuk J., Ork B., Hart B.J., Mazur S., Holbrook M.R., Frieman M.B., Traynor D., Johnson R.F., Dyall J., Kuhn J.H., et al. Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis. Antimicrob. Agents Chemother. 2015;59:1088–1099. doi: 10.1128/AAC.03659-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.DeDiego M.L., Nieto-Torres J.L., Regla-Nava J.A., Jimenez-Guardeño J.M., Fernandez-Delgado R., Fett C., Castaño-Rodriguez C., Perlman S., Enjuanes L. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J. Virol. 2014;88:913–924. doi: 10.1128/JVI.02576-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Dosch S.F., Mahajan S.D., Collins A.R. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro. Virus Res. 2009;142:19–27. doi: 10.1016/j.virusres.2009.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Peteranderl C., Herold S. The Impact of the Interferon/TNF-Related Apoptosis-Inducing Ligand Signaling Axis on Disease Progression in Respiratory Viral Infection and Beyond. Front. Immunol. 2017;8 doi: 10.3389/fimmu.2017.00313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Mizutani T. Signal Transduction in SARS-CoV-Infected Cells. Ann. N. Y. Acad. Sci. 2007;1102:86–95. doi: 10.1196/annals.1408.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Liang T., Chen X., Su M., Chen H., Lu G., Liang K. Vitamin C exerts beneficial hepatoprotection against Concanavalin A-induced immunological hepatic injury in mice through inhibition of NF-κB signal pathway. Food Funct. 2014;5:2175–2182. doi: 10.1039/C4FO00224E. [DOI] [PubMed] [Google Scholar]
  • 91.Zhu H., Bian C., Yuan J., Chu W., Xiang X., Chen F., Wang C., Feng H., Lin J.-K. Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-κB signaling pathway in experimental traumatic brain injury. J. Neuroinflammation. 2014;11:59. doi: 10.1186/1742-2094-11-59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Kong F., Ye B., Cao J., Cai X., Lin L., Huang S., Huang W., Huang Z. Curcumin Represses NLRP3 Inflammasome Activation via TLR4/MyD88/NF-κB and P2X7R Signaling in PMA-Induced Macrophages. Front. Pharmacol. 2016;7:369. doi: 10.3389/fphar.2016.00369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Vucic M., Cojbasic I., Vucic J., Pavlovic V. The effect of curcumin and PI3K/Akt inhibitor on monosodium glutamate-induced rat thymocytes toxicity. Gen. Physiol. Biophys. 2018;37:329–336. doi: 10.4149/gpb_2017050. [DOI] [PubMed] [Google Scholar]
  • 94.Gong P., Liu M., Hong G., Li Y., Xue P., Zheng M., Wu M., Shen L., Yang M., Diao Z., et al. Curcumin improves LPS-induced preeclampsia-like phenotype in rat by inhibiting the TLR4 signaling pathway. Placenta. 2016;41:45–52. doi: 10.1016/j.placenta.2016.03.002. [DOI] [PubMed] [Google Scholar]
  • 95.Yao L., Sun T. Glycyrrhizin administration ameliorates Streptococcus aureus-induced acute lung injury. Int. Immunopharmacol. 2019;70:504–511. doi: 10.1016/j.intimp.2019.02.046. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Nutrients are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES